Bristol Myers Squibb Company
NEWS
Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced it is buying cardiology company MyoKardia for about $13.1 billion. The deal is expected to close before the end of the year.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
BMS’s ongoing Phase III randomized, double-blind, multi-center study – named CheckMate-274 – compares Opdivo against a placebo in 709 participants deemed to be at a high risk of recurrence after radical surgery.
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
JOBS
IN THE PRESS